Table 1.
Patients and tumor characteristics, all-cause and BC-specific deaths, overall and by menopausal-status. Naples, Italy, 2009-2022.
| Variables | All | Pre-menopausal | Post-menopausal | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N1 (%) | Deaths from all-causes | Deaths from breast cancer | N1 (%) | Deaths from all-causes | Deaths from breast cancer | N1 (%) | Deaths from all-causes | Deaths from breast cancer | |
| 955 | 208 | 131 | 369 | 34 | 31 | 586 | 174 | 100 | |
| Center | |||||||||
| IRCCS G. Pascale | 526 (55) | 137 | 87 | 196 (53) | 20 | 19 | 330 (56) | 117 | 68 |
| Policlinico Federico II | 429 (45) | 71 | 44 | 173 (47) | 14 | 12 | 256 (44) | 57 | 32 |
| Age (years) | |||||||||
| < 40 | 93 (10) | 15 | 14 | 92 (25) | 15 | 14 | 1 (0) | 0 | 0 |
| 40–49 | 249 (26) | 21 | 17 | 232 (63) | 16 | 14 | 17 (3) | 5 | 3 |
| 50–59 | 257 (27) | 52 | 41 | 45 (12) | 3 | 3 | 212 (36) | 49 | 38 |
| ≥ 60 | 356 (37) | 120 | 59 | 0 | 0 | 0 | 356 (61) | 120 | 59 |
| ER | |||||||||
| Negative (0) | 172 (18) | 49 | 36 | 57 (15) | 10 | 9 | 115 (20) | 39 | 27 |
| Positive (>0) | 781 (82) | 159 | 95 | 311 (84) | 24 | 22 | 470 (80) | 135 | 73 |
| PGR | |||||||||
| Negative (0) | 217 (23) | 65 | 47 | 68 (18) | 13 | 12 | 149 (25) | 52 | 35 |
| Positive (>0) | 736 (77) | 143 | 84 | 300 (81) | 21 | 19 | 436 (74) | 122 | 65 |
| Ki67>20 | |||||||||
| Negative (<20%) | 547 (58) | 95 | 53 | 172 (47) | 11 | 11 | 295 (50) | 84 | 42 |
| Positive (≥20%) | 398 (42) | 112 | 77 | 194 (53) | 22 | 19 | 287 (49) | 90 | 58 |
| Surrogate molecular subtypes | |||||||||
| Luminal A-like | 310 (33) | 59 | 30 | 110 (30) | 3 | 3 | 200 (34) | 56 | 27 |
| Luminal B-like/HER2- | 341 (37) | 75 | 50 | 141 (38) | 15 | 13 | 200 (34) | 60 | 37 |
| HER2+ | 152 (16) | 34 | 23 | 67 (18) | 6 | 6 | 85 (15) | 28 | 17 |
| Triple negative | 123 (13) | 33 | 26 | 40 (11) | 9 | 8 | 83 (14) | 24 | 18 |
| HR status | |||||||||
| HR– | 158 (17) | 48 | 36 | 49 (13) | 9 | 9 | 109 (19) | 39 | 27 |
| HR+ | 795 (83) | 160 | 95 | 319 (86) | 25 | 22 | 476 (81) | 135 | 73 |
| Cancer stage | |||||||||
| I–IIA | 614 (64) | 110 | 57 | 244 (66) | 18 | 16 | 370 (63) | 92 | 41 |
| IIB | 125 (13) | 30 | 19 | 46 (13) | 7 | 7 | 79 (14) | 23 | 12 |
| IIIA–IIIC | 174 (18) | 56 | 45 | 68 (18) | 8 | 7 | 106 (18) | 48 | 38 |
| Tumor dimension (T) | |||||||||
| T1 | 530 (56) | 96 | 54 | 215 (58) | 15 | 13 | 315 (54) | 81 | 41 |
| T2 | 352 (37) | 89 | 60 | 125 (34) | 16 | 15 | 227 (39) | 73 | 45 |
| T3–T4 | 49 (5) | 17 | 13 | 22 (6) | 3 | 3 | 27 (5) | 14 | 10 |
| Axillary nodal status (N) | |||||||||
| N0 | 513 (54) | 92 | 42 | 193 (52) | 15 | 13 | 320 (55) | 77 | 29 |
| N+ | 413 (43) | 107 | 82 | 169 (46) | 18 | 17 | 244 (42) | 89 | 65 |
| Histological grade | |||||||||
| G1 | 57 (6) | 7 | 1 | 26 (7) | 0 | 0 | 31 (5) | 7 | 1 |
| G2 | 386 (40) | 85 | 48 | 140 (38) | 10 | 10 | 246 (42) | 75 | 38 |
| G3 | 490 (51) | 105 | 73 | 197 (53) | 21 | 18 | 293 (50) | 84 | 55 |
| Cancer type | |||||||||
| Invasive ductal carcinoma | 710 (74) | 158 | 106 | 281 (76) | 31 | 28 | 429 (73) | 127 | 78 |
| Invasive lobular carcinoma | 149 (16) | 32 | 16 | 52 (14) | 1 | 1 | 97 (17) | 31 | 15 |
| Tubular carcinoma | 31 (3) | 4 | 2 | 15 (4) | 0 | 0 | 16 (3) | 4 | 2 |
| Other | 65 (7) | 14 | 7 | 21 (6) | 2 | 2 | 44 (8) | 12 | 5 |
| Treatments | |||||||||
| No therapy | 59 (7) | 7 | 3 | 19 (5) | 2 | 1 | 40 (7) | 5 | 2 |
| Adjuvant/neoadjuvant | 120 (14) | 31 | 22 | 50 (14) | 9 | 9 | 70 (12) | 22 | 13 |
| Hormone | 678 (79) | 118 | 65 | 266 (72) | 13 | 12 | 412 (70) | 105 | 53 |
| Body mass index, kg/m2 | |||||||||
| N | 933 | 202 | 127 | 359 (97) | 33 | 30 | 574 (98) | 169 | 97 |
| < 25 | 341 (37) | 57 | 36 | 194 (53) | 15 | 12 | 147 (25) | 42 | 24 |
| 25–30 | 317 (34) | 67 | 36 | 112 (30) | 12 | 12 | 205 (35) | 55 | 24 |
| ≥ 30 | 275 (29) | 78 | 55 | 53 (14) | 6 | 6 | 222 (38) | 72 | 49 |
| Waist circumference, cm | |||||||||
| N | 900 | 192 | 124 | 347 (94) | 31 | 29 | 553 (94) | 162 | 95 |
| < 88 | 410 (46) | 64 | 41 | 225 (61) | 15 | 14 | 185 (32) | 49 | 27 |
| ≥ 88 | 490 (54) | 129 | 83 | 122 (33) | 16 | 15 | 368 (63) | 113 | 68 |
| Waist-to-hip ratio, u | |||||||||
| N | 899 | 192 | 124 | 348 (94) | 31 | 29 | 551 (94) | 161 | 95 |
| ≤ 0.85 | 322 (36) | 46 | 32 | 184 (50) | 13 | 12 | 138 (24) | 33 | 20 |
| > 0.85 | 577 (64) | 146 | 92 | 164 (44) | 18 | 17 | 413 (71) | 128 | 75 |
| Metabolic syndrome (MetS)2 | |||||||||
| No | 545 (76) | 95 | 65 | 271 (93) | 24 | 23 | 274 (64) | 71 | 42 |
| Yes | 173 (24) | 64 | 42 | 21 (7) | 2 | 2 | 152 (36) | 62 | 40 |
| MetS components | |||||||||
| None | 122 (19) | 11 | 10 | 81 (36) | 6 | 6 | 41 (10) | 5 | 4 |
| 1–2 | 331 (53) | 75 | 48 | 125 (55) | 15 | 14 | 206 (52) | 60 | 34 |
| ≥ 3 | 173 (28) | 64 | 42 | 21 (69) | 2 | 2 | 152 (38) | 62 | 40 |
ER estrogen receptor, PGR progesterone receptor, HER2 human epidermal growth factor receptor-2, HR hormone receptor.
1For some variables the sum does not add up to the total due to missing values.
2MetS was defined by the presence of 3 to 5 of the following criteria: WC ≥88 cm, blood pressure ≥ 130/ ≥ 85 mmHg, fasting (at least 8-hour fasting) concentration of serum triglycerides ≥ 150 mg/dL, high-density protein cholesterol (HDL-C) < 50 mg/dL and fasting plasma glucose concentration ≥ 110 mg/dL.